干燥综合征合并原发性胆汁性肝硬化患者的外周血Th17/Treg细胞百分比及临床特征

肝脏 ›› 2020, Vol. 25 ›› Issue (2): 155-157.

干燥综合征合并原发性胆汁性肝硬化患者的外周血Th17/Treg细胞百分比及临床特征

郇稳, 史丽璞

450003 郑州人民医院风湿免疫科(郇稳);河南省人民医院风湿免疫科(史丽璞)

收稿日期:2019-08-04 出版日期:2020-02-29 发布日期:2020-03-26
基金资助:
河南省科技厅项目(182102310546)

Percentage of Th17/Treg cells in peripheral blood of patients with Sjogren's syndrome and primary biliary cirrhosis and their clinical characteristics

HUAN Wen¹,SHI Li-pu²

1.Department of Rheumatology and Immunology, People's Hospital of Zhengzhou, Henan 450003,China;
2.Department of Rheumatology and Immunology, Henan Provincial People's Hospital,Zhengzhou, Henan 450008,China

Received:2019-08-04 Online:2020-02-29 Published:2020-03-26

摘要/Abstract

摘要： 目的通过对SS合并PBC患者中外周血Th17和Treg细胞的检测,分析其临床特征,并探明Th17、Treg细胞对SS合并PBC患者的影响。方法选择2012年3月至2018年2月期间郑州人民医院收治的SS合并PBC患者22例,SS患者48例,选取健康志愿者68名。比较3组研究对象的肝功能指标、Th17、Treg和TH17/Treg水平。组间比较采用t检验或Kruskal-Wallis H检验;计数资料以百分比表示,组间比较采用卡方检验。结果 SS合并PBC组出现黄疸、皮肤瘙痒、腹水、消化道出血、口干、食管静脉曲张、发热及眼部干涩等主要临床表现为20例(90.9%,20/22),高于对照组37例(77.1%,37/48),(P<0.05)。而体质量减轻的患者SS组(46例,95.8%)明显多于SS合并PBC组(17例,77.3%),(P<0.05)。SS合并PBC组患者ALT、AST、碱性磷酸酶(ALP)、γ-谷氨酰胺酶(γ-GT)和TBil均高于SS组和健康组(P<0.05)。SS合并PBC组患者Th17细胞百分比为[16.6(10.1,22.5)%],明显高于SS组[9.4(7.0,13.0)%,P<0.05]及健康组[4.9(4.3,9.8)%,P<0.05];SS合并PBC组Th17/Treg细胞比值[0.52(0.42,0.62)]均明显高于SS组[0.25(0.14,0.37),P<0.05]及健康组[0.22(0.13,0.26),P<0.05]。结论 SS合并PBC患者外周血Th17/Treg细胞水平及其比值明显失衡,提示Th17细胞在很大程度上参与了致病过程。此外,Th17/Treg比值与某些肝功能指标有一定的相关性。

关键词: 干燥综合征, 原发性胆汁性肝硬化, 调节性T淋巴细胞, 辅助性T淋巴细胞17

Abstract: Objective To detect the levels of T helper 17 (Th17) and regulatory T (Treg) cells in peripheral blood of Sjogren's syndrome (SS) patients combined with primary biliary cirrhosis (PBC), to analyze their clinical characteristics, and to investigate the effects of Th17/Treg cells on these patients. Methods A total of 22 patients with SS complicated with PBC aged (54.1 ± 9.6) years, including 7 males and 15 females, and 48 SS patients aged (56.7 ± 10.2) years, including 10 males and 38 females, in our hospital from March 2012 to February 2018 were enrolled. And 68 healthy volunteers were enrolled, including 16 males and 52 females, with an average age of (55.2 ± 4.5) years. The measurement data of normal distribution are expressed by mean ± standard deviation, the measurement data of non-normal distribution are expressed by median (percentage 25, percentage 75)], and the comparison between the groups is conducted by t test or Kruskal-Wallis H test. Counting data are expressed as percentages, and comparisons between the groups are made by chi-square test. Results There were 20 cases (90.9%) in the observation group (SS combined with PBC) with the main clinical manifestations of jaundice, skin pruritus, ascites, gastrointestinal hemorrhage, dry mouth, esophageal varices, fever and dry eyes, higher than 37 cases (77.1%) in the control group (SS). However, the number of patients with weight loss in the control group (46, 95.8%) was significantly higher than that in the observation group (17, 77.3%). The alanine aminotransferase, aspartate transaminase, alkaline phosphatase, γ -glutaminase and total bilirubin in the observation group were higher than those in the control group and the healthy group (P<0.05). The percentage of Th17 cells in the observation group was 16.6% (10.1%, 22.5%), significantly higher than that in the control group [9.4% (7.0%, 13.0%), P<0.05] and the healthy group [4.9% (4.3%, 9.8%%, P<0.05]. The ratio of Th17/Treg cells in observation group [0.52 (0.42, 0.62)] was significantly higher than that in control group [0.25 (0.14, 0.37), P<0.05] and healthy group [0.22 (0.13, 0.26), P<0.05]. Conclusion The levels of Th17/Treg cells and their ratios in peripheral blood of SS patients with PBC are obviously out of balance, suggesting that Th17 cells are very likely to be involved in the pathogenesis process. In addition, Th17/Treg ratio has certain correlation with some liver function indexes, and further hierarchical analysis can be carried out stratified by the severity of the disease in future studies.

Key words: Sjogren's syndrome, Primary biliary cirrhosis, Regulatory cell, T helper cell 17

郇稳, 史丽璞. 干燥综合征合并原发性胆汁性肝硬化患者的外周血Th17/Treg细胞百分比及临床特征[J]. 肝脏, 2020, 25(2): 155-157.

HUAN Wen,SHI Li-pu. Percentage of Th17/Treg cells in peripheral blood of patients with Sjogren's syndrome and primary biliary cirrhosis and their clinical characteristics[J]. Chinese Hepatolgy, 2020, 25(2): 155-157.

参考文献

[1] Mavragani CP, Nezos A, Moutsopoulos HM. New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol, 2013, 25:623-629.
[2] Wei W, Ahmad SS, Chi S, et al. From molecular mechanism to the etiology of Sjogren Syndrome. Curr Pharm Des, 2018, 24:4177-4185.
[3] Cafaro G, Croia C, Argyropoulou OD, et al. One year in review 2019: Sjogren's syndrome. Clin Exp Rheumatol, 2019, 37 Suppl 118:3-15.
[4] Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum, 2008, 58:734-743.
[5] Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol, 2014, 10:1667-1678.
[6] Gonzalez RS, Washington K. Primary Biliary Cholangitis and Autoimmune Hepatitis. Surg Pathol Clin, 2018, 11:329-349.
[7] Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J, 2000, 76:199-206.
[8] Kim KA, Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Korean J Hepatol, 2011, 17:173-179.
[9] Selmi C, Invernizzi P, Keeffe EB, et al. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol, 2004, 38:264-271.
[10] Ge J, Wang K, Meng QH, et al. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol, 2010, 30:60-67.
[11] Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev, 2014, 13:668-677.
[12] Li X, Yuan FL, Lu WG, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun, 2010, 397:131-135.
[13] Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol, 2008, 8:523-532.
[14] Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol, 2007, 148:32-46.
[15] Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity, 2007, 26:579-591.